Example: Heart Attack

Search clinical trials for: Sorafenib

Total 780 results

NCT04479527

Not yet recruiting

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma
NCT04476329

Not yet recruiting

Optimization for Regorafenib in HCC

Conditions: Hepatocellular Carcinoma
NCT04465734

Not yet recruiting

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Conditions: Hepatocellular Carcinoma (HCC)
NCT04387695

Recruiting

SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

Conditions: Unresectable Hepatocellular Carcinoma; Portal Vein Thrombosis
NCT04353765

Recruiting

Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Conditions: Locally Advanced or Metastatic Renal Cell Carcinoma
NCT04344158

Not yet recruiting

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Conditions: Advanced Hepatocellular Carcinoma (HCC)
NCT04326439

Recruiting

AflacLL1901 (CHOA-AML)

Conditions: Acute Myeloid Leukemia; AML, Childhood
NCT04317248

Not yet recruiting

"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma
NCT04316182

Not yet recruiting

Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)

Conditions: Hepatocellular Carcinoma
NCT04229355

Not yet recruiting

DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma
NCT04232722

Recruiting

Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation

Conditions: HCC
NCT04170556

Recruiting

Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)

Conditions: Hepatocellular Carcinoma
NCT04162158

Recruiting

Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma
NCT04163237

Recruiting

Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer

Conditions: Advanced Liver Cancer
NCT04152356

Recruiting

Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma

Conditions: HepatoCellular Carcinoma
NCT04143191

Recruiting

Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC

Conditions: Hepatocellular Carcinoma
NCT04135690

Recruiting

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Conditions: Hepatocellular Carcinoma
NCT04127396

Enrolling by invitation

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

Conditions: Carcinoma, Hepatocellular; Portal Vein Tumor Thrombus
NCT04103398

Not yet recruiting

TACE Plus Sorafenib Versus TACE Alone for Recurrent Unresectable Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma; Sorafenib; Transarterial Chemoembolization
NCT04069949

Not yet recruiting

Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus

Conditions: Unresectable Hepatocellular Cancer; Portal Vein Tumor Thrombus
NCT04051853

Terminated

Sorafenib PK in Patients With Advanced HCC and Child-Pugh B

Conditions: BCLC Stage C HCC; CP-B Liver Cirrhosis
NCT04039607

Recruiting

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma
NCT04000737

Recruiting

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Conditions: Advanced Hepatocellular Carcinoma
NCT03971201

Not yet recruiting

A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion

Conditions: Hepatocellular Cancer
NCT03965546

Recruiting

ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer

Conditions: Hepatocellular Carcinoma; Liver Cancer; Liver Neoplasms; Metastatic Liver Cancer
NCT03958669

Recruiting

Fingerprint Characterization of Sorafenib Treated HCC

Conditions: Hepatocellular Carcinoma; Sorafenib
NCT03956940

Recruiting

Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib

Conditions: Hepatocarcinoma
NCT03899428

Recruiting

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Conditions: Hepatocellular Carcinoma
NCT03892577

Recruiting

Real-world Study for Patients With Advanced Hepatobiliary Tumors

Conditions: Objective Response Rate; Progression-free Survival; Overall Survival; Disease Control Rate; Duration of Response; Five-year Survival Rate; Quality of Life
NCT03878524

Recruiting

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma
NCT03812770

Recruiting

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

Conditions: Hepatocellular Carcinoma
NCT03812783

Recruiting

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Conditions: Hepatocellular Carcinoma
NCT03794440

Recruiting

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Conditions: Hepatocellular Carcinoma
NCT03780634

Withdrawn

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Conditions: Hepatocellular Carcinoma
NCT03775395

Recruiting

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC

Conditions: Hepatocellular Carcinoma
NCT03768375

Recruiting

Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
NCT03764293

Recruiting

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Conditions: Locally Advanced or Metastatic and Unresectable HCC
NCT03755791

Recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

Conditions: Hepatocellular Carcinoma
NCT03730675

Recruiting

Irradiation Stent Placement Plus TACE for HCC and PVTT

Conditions: Hepatocellular Carcinoma; Portal Vein Tumor Thrombosis
NCT03722498

Terminated

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Conditions: Hepatocellular Carcinoma
NCT03680677

Suspended

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Conditions: Leukemia, Acute; MDS
NCT03674060

Completed

Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers

Conditions: Healthy, Male
NCT03645980

Recruiting

DKN-01 Inhibition in Advanced Liver Cancer

Conditions: Hepatocellular Carcinoma
NCT03644511

Terminated

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

Conditions: Hepatocellular Carcinoma
NCT03642236

Enrolling by invitation

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Conditions: FLT3-ITD Mutation; Acute Myeloid Leukemia; Brutons Tyrosine Kinase
NCT03630120

Active, not recruiting

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Conditions: Thyroid Cancer; Thyroid Cancer, Medullary; Differentiated Thyroid Cancer; Papillary Thyroid Cancer; Follicular Thyroid Cancer; Poorly Differentiated Thyroid Gland Carcinoma
NCT03622541

Completed

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

Conditions: FLT3-ITD Mutation; AML
NCT03606590

Active, not recruiting

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

Conditions: Hepatocellular Carcinoma
NCT03586973

Active, not recruiting

A Phase 2 Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma

Conditions: Advanced Hepatocellular Carcinoma
NCT03582618

Recruiting

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma; Advanced Cancer

Search clinical trials for: Sorafenib

Recent CRA jobs

Scientist - BioAnalytics

Finance Assistant (6 months internship)

Digital Implementation Manager - eCOA (remote)

Sr CM Analyst I

Project Manager - Central Lab

Shipping/ Receiving Coordinator

Associate Scientist / Scientist - GMP , Pilot Plant , Small Molecule

Principal Database Programmer (UK, Spain, Romania, Poland, Ireland)

Global Category Sourcing Manager - Clinical Lab

Clinical Research Physician